BioXcel Therapeutics (BTAIQ) EBITDA Margin (2022 - 2026)
BioXcel Therapeutics' EBITDA Margin was -5590.66% in Q2 2026, up 7556.84 percentage points from -13147.50% a year earlier but down 656.19 percentage points from the prior quarter.
Powered by 
Analysis
BioXcel Therapeutics (BTAIQ) EBITDA Margin (2022 - 2026) Analysis & Trends
On a trailing twelve-month basis, BioXcel Therapeutics' EBITDA Margin was -6024.39% through Jun 30, 2026, down 99.05 percentage points year-over-year; for FY2025, it came in at -7813.24%, down 4859.31 percentage points from FY2024.
- EBITDA Margin shows a three-year change of +34671.56 percentage points (FY2022 to FY2025).
- In earlier years, EBITDA Margin was -2953.93% in FY2024 (+9471.00 pp), -12424.93% in FY2023 (+30059.87 pp) and -42484.80% in FY2022.
- Quarterly EBITDA Margin has moved between -28397.81% (Q3 2022) and -1559.69% (Q2 2024) over five years.
- Compared with a year earlier, EBITDA Margin was higher in four of the last eight quarters, with an average year-over-year change of -481.39 percentage points.
- The best year-over-year quarter for EBITDA Margin over five years was Q1 2024 (a gain of 20676.25 percentage points); the worst was Q2 2025 (a drop of 11587.81 percentage points).
- Per Business Quant data, BTAIQ's EBITDA Margin in the three quarters before Q2 2026 was -4934.47% (Q1 2026), -3987.50% (Q4 2025) and -14441.84% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 39.10% |
| 10 | BioXcel Therapeutics | 1.57 Mn | 1.57 Mn | 160,000.00 | -5,590.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,590.66% |
| Mar 31, 2026 | -4,934.47% |
| Dec 31, 2025 | -3,987.50% |
| Sep 30, 2025 | -14,441.84% |
| Jun 30, 2025 | -13,147.50% |
| Mar 31, 2025 | -5,966.07% |
| Dec 31, 2024 | -2,845.90% |
| Sep 30, 2024 | -7,110.28% |
| Jun 30, 2024 | -1,559.69% |
| Mar 31, 2024 | -4,138.32% |
| Dec 31, 2023 | -5,265.16% |
| Sep 30, 2023 | -14,140.18% |
| Jun 30, 2023 | -11,451.42% |
| Mar 31, 2023 | -24,814.56% |
| Dec 31, 2022 | -22,190.34% |
| Sep 30, 2022 | -28,397.81% |
API Access
BioXcel Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=BTAIQ&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "BTAIQ", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=BTAIQ&period=max&api_key=YOUR_API_KEY");
const data = await res.json();